| Category | Key points | Key recent sources |
|---|---|---|
| Identity/Domain | • Verified target context: rat **Tp53** encodes cellular tumor antigen **p53**, a conserved p53-family transcription factor consistent with UniProt P10361.
• Conserved domain architecture includes N-terminal transactivation regions, proline-rich region, central DNA-binding domain, oligomerization/tetramerization domain, and C-terminal regulatory region.
• Functional p53 acts as a **tetramer**; tetramerization is required for efficient DNA binding and full transactivation. | • Liu et al., 2024, *Cancer Cell* — https://doi.org/10.1016/j.ccell.2024.04.009 (pqac-00000001)
• Shen et al., 2023, *MedComm* — https://doi.org/10.1002/mco2.288 (pqac-00000003)
• Benitez et al., 2024, *Biomedicines* — https://doi.org/10.3390/biomedicines12071453 (pqac-00000006) |
| Molecular function | • Primary function is **sequence-specific DNA-binding transcription factor** activity, activating or repressing stress-response genes.
• Canonical outputs include **cell-cycle arrest**, **DNA repair**, **apoptosis**, and **senescence**.
• Representative downstream effectors include **CDKN1A/p21**, **BAX**, **PUMA**, and **NOXA**; p53 can also promote apoptosis through non-transcriptional mitochondrial actions. | • Wang et al., 2023, *Signal Transduction and Targeted Therapy* — https://doi.org/10.1038/s41392-023-01347-1 (pqac-00000002, pqac-00000004)
• Grigoreva et al., 2024, *Pharmaceuticals* — https://doi.org/10.3390/ph17121682 (pqac-00000000, pqac-00000007)
• Tornesello, 2024, *Int J Mol Med* — https://doi.org/10.3892/ijmm.2024.5448 (pqac-00000012, pqac-00000013) |
| Regulation | • Under basal conditions, p53 abundance is kept low mainly by **MDM2/MDMX-mediated ubiquitination** and proteasomal turnover.
• Stress signals such as DNA damage activate **ATM/ATR/Chk** pathways, promoting post-translational modifications that stabilize and activate p53.
• p53 induces **MDM2** transcription, creating a classic negative-feedback loop; PTMs also influence tetramer assembly and promoter selectivity. | • Wang et al., 2023 — https://doi.org/10.1038/s41392-023-01347-1 (pqac-00000002, pqac-00000004)
• Grigoreva et al., 2024 — https://doi.org/10.3390/ph17121682 (pqac-00000000, pqac-00000007)
• Pasadas, 2024 — https://doi.org/10.5821/dissertation-2117-422069 (pqac-00000016) |
| Localization | • p53 functions predominantly in the **nucleus**, where stress-stabilized tetramers bind p53 response elements in promoters/enhancers.
• It is also present in the **cytoplasm** and can relocalize to **mitochondria** for transcription-independent apoptotic signaling.
• MDM2-mediated ubiquitination contributes to nuclear export and degradation. | • Wang et al., 2023 — https://doi.org/10.1038/s41392-023-01347-1 (pqac-00000004)
• Pasadas, 2024 — https://doi.org/10.5821/dissertation-2117-422069 (pqac-00000005, pqac-00000016)
• Grigoreva et al., 2024 — https://doi.org/10.3390/ph17121682 (pqac-00000007) |
| Pathways/Processes | • Core pathway role: **DNA damage response** linking genotoxic or oncogenic stress to transcriptional reprogramming.
• Major biological processes include **G1/G2 checkpoint control**, DNA repair facilitation, apoptosis, senescence, metabolism, autophagy, and ferroptosis-related regulation.
• p53 pathway logic is summarized in recent pathway schematics integrating ATM/ATR, MDM2/MDMX, and downstream targets. | • Wang et al., 2023 — https://doi.org/10.1038/s41392-023-01347-1 (pqac-00000002, pqac-00000004, pqac-00000024)
• Pant et al., 2023, *Cell Death Differ* — https://doi.org/10.1038/s41418-023-01123-2 (pqac-00000006)
• Liu et al., 2024 — https://doi.org/10.1016/j.ccell.2024.04.009 (pqac-00000001) |
| Rat-specific evidence | • Direct rat-relevant evidence exists for a **p53–TLR3 axis**: multiple p53 consensus elements were identified in the **TLR3** gene across species including **Rattus norvegicus**.
• In rat lung **CD117+ endothelial cells**, clonal expansion reduced **Tp53** and **Tlr3** expression; **Nutlin-3a** blocked clonogenic expansion.
• Rat Tp53 silencing lowered **Tlr3** and **Id1** mRNA and increased angiogenic behavior, linking rat Tp53 to pulmonary vascular homeostasis. | • Bhagwani et al., 2023, *iScience* — https://doi.org/10.1016/j.isci.2023.105935 (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000011) |
| Disease relevance/statistics | • **TP53 is the most frequently mutated gene in human cancer**; mutation/inactivation occurs in **~50%** of cancers, with frequencies >50% in at least 20 tumor types.
• **>80%** of TP53 alterations are missense mutations, concentrated in the DNA-binding domain; ~30% of missense mutations cluster at hotspot codons.
• In tumors with one mutant TP53 allele, **>90%** reportedly lose the second allele by LOH/deletion/mutation, underscoring tumor-suppressor function. | • Tornesello, 2024 — https://doi.org/10.3892/ijmm.2024.5448 (pqac-00000012, pqac-00000013)
• Wang et al., 2023 — https://doi.org/10.1038/s41392-023-01347-1 (pqac-00000015)
• Pasadas, 2024 — https://doi.org/10.5821/dissertation-2117-422069 (pqac-00000016, pqac-00000017) |
| Therapies/applications | • Current translational strategy for **TP53-wild-type** tumors is pharmacologic **MDM2–p53 inhibition** to reactivate endogenous p53.
• In the 2024 first-in-human **alrizomadlin (APG-115)** trial, **MTD 150 mg**, **RP2D 100 mg**; grade 3–4 TRAEs included thrombocytopenia and neutropenia, with pharmacodynamic evidence of p53 activation.
• Among 20 evaluable patients, **ORR 10%**, **stable disease 50%**, median **PFS 6.1 months**; in **MDM2-amplified/TP53-wild-type** tumors, **ORR 25% (2/8)** and **DCR 100% (8/8)**; several ongoing APG-115 and brigimadlin trials support real-world clinical implementation. | • Zhang et al., 2024, *ESMO Open* — https://doi.org/10.1016/j.esmoop.2024.103636 (pqac-00000020, pqac-00000022)
• Gollner et al., 2024, *Mol Cancer Ther* — https://doi.org/10.1158/1535-7163.mct-23-0783 (pqac-00000021, pqac-00000023)
• Clinical trials: NCT02935907, NCT03611868, NCT03449381, NCT05218499 |
*Table: This table condenses the most relevant functional-annotation evidence for rat Tp53 (UniProt P10361), spanning identity, molecular function, regulation, localization, pathways, rat-specific experiments, disease statistics, and therapeutic applications. It is designed to support a comprehensive narrative report with recent, citable sources.*